Updated on 2024/04/30

写真a

 
Kato Yasuhiro
 
Affiliation
Chibahokusoh Hospital, Department of Pulmonary Medicine, Assistant Professor
Title
Assistant Professor
External link

Research Interests

  • Thoracic oncology

  • Lung cancer

  • 薬剤耐性

  • 分子標的治療薬

Research Areas

  • Life Science / Respiratory medicine

Education

  • Nippon Medical School   Medical School

    2005.4 - 2011.3

    　 More details

  • Nippon Medical School

    2018.3

    　 More details

Research History

  • 日本医科大学千葉北総病院   助教

    2023.10

    　 More details

  • 日本医科大学付属病院   呼吸器内科   助教

    2023.6 - 2023.9

    　 More details

  • 日本医科大学付属病院   総合診療科   助教

    2022.10 - 2023.5

    　 More details

  • 日本医科大学付属病院   呼吸器内科   リサーチアシスタント

    2022.4 - 2022.9

    　 More details

  • 公立福生病院   内科   医長

    2021.10 - 2022.3

    　 More details

  • 慈生会等潤病院   内科   医長

    2021.4 - 2021.9

    　 More details

  • 日本医科大学付属病院   呼吸器内科   リサーチアシスタント

    2020.11 - 2021.3

    　 More details

  • 埼玉県立がんセンター   呼吸器内科   医長

    2019.4 - 2020.10

    　 More details

  • がん・感染症センター都立駒込病院   呼吸器内科   医員

    2017.4 - 2019.3

    　 More details

  • 日本医科大学千葉北総病院   呼吸器内科   助教

    2015.4 - 2017.3

    　 More details

▼display all

Papers

  • Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer. International journal

    Takehiro Tozuka, Rintaro Noro, Keisuke Yoshida, Satoshi Takahashi, Mariko Hirao, Kuniko Matsuda, Yasuhiro Kato, Shinji Nakamichi, Susumu Takeuchi, Masaru Matsumoto, Akihiko Miyanaga, Shinobu Kunugi, Kazufumi Honda, Jun Adachi, Masahiro Seike

    JTO clinical and research reports   5 ( 4 )   100668 - 100668   2024.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    INTRODUCTION: Osimertinib is a standard treatment for patients with EGFR-mutant NSCLC. Although some osimertinib resistance mechanisms have been identified, nearly 50% of the mechanisms remain to be elucidated. This study was aimed at identifying non-genetic mechanisms underlying osimertinib resistance. METHODS: We established two osimertinib-resistant cell lines from EGFR mutation-positive PC-9 and HCC827 NSCLC cell lines (PC-9OR and HCC827OR, respectively) using a stepwise method. We compared the phosphoproteomic profiles of the osimertinib-resistant and parental cells using mass spectrometry. Upstream kinases were identified using the application Kinase Enrichment Analysis version 3. RESULTS: Phosphoproteomic analysis revealed 80 phosphorylation sites that were mutually up-regulated in PC-9OR and HCC827OR cells. The Kinase Enrichment Analysis version 3 analysis identified focal adhesion kinase (FAK) and proto-oncogene tyrosine-protein kinase Src (Src) as upstream kinases of these up-regulated phosphoproteins. The small-interfering RNA-mediated knockdown of FAK reduced Src phosphorylation and that of Src reduced FAK phosphorylation in both cell lines. Furthermore, FAK- or Src-specific small-interfering RNA treatments restored EGFR phosphorylation in PC-9OR and HCC827OR cells. The combination of FAK and Src inhibitors inhibited PC-9OR and HCC827OR cell proliferation in vitro and suppressed tumor growth in a xenograft mouse model. Immunohistochemistry of tumors from patients with EGFR-mutant NSCLC suggested that phosphorylated FAK and Src are involved in initial and acquired resistance to osimertinib. CONCLUSIONS: Phosphoproteomic analysis may help elucidate the mechanisms of resistance to molecular-targeted therapies in lung cancer. Mutual phosphorylation of FAK and Src is involved in osimertinib resistance. Thus, FAK and Src inhibition may be novel treatment strategies for osimertinib-resistant NSCLC.

    DOI： 10.1016/j.jtocrr.2024.100668

    PubMed

    researchmap

  • HMGCS2によるメバロン酸経路を介したNTRK阻害薬に対する耐性誘導とその克服(HMGCS2 Induces resistance to NTRK inhibitors via mevalonate pathway)

    加藤 泰裕, 松本 優, 高野 夏希, 平尾 真季子, 松田 久仁子, 戸塚 猛大, 恩田 直美, 中道 真仁, 武内 進, 宮永 晃彦, 野呂 林太郎, 弦間 昭彦, 清家 正博

    日本癌学会総会記事   82回   421 - 421   2023.9

    　More details

    Language：English   Publisher：(一社)日本癌学会  

    researchmap

  • 悪性胸膜中皮腫との鑑別に苦慮した悪性リンパ腫の1例

    芳賀 三四郎, 柏田 建, 恩田 直美, 加藤 泰裕, 高野 夏希, 福泉 彩, 武内 進, 松本 優, 宮永 晃彦, 笠原 寿郎, 清家 正博, 功刀 しのぶ, 寺崎 泰弘

    肺癌   63 ( 4 )   332 - 332   2023.8

    　More details

    Language：Japanese   Publisher：(NPO)日本肺癌学会  

    researchmap

  • 悪性胸膜中皮腫との鑑別に苦慮した悪性リンパ腫の1例

    芳賀 三四郎, 柏田 建, 恩田 直美, 加藤 泰裕, 高野 夏希, 福泉 彩, 武内 進, 松本 優, 宮永 晃彦, 笠原 寿郎, 清家 正博, 功刀 しのぶ, 寺崎 泰弘

    肺癌   63 ( 4 )   332 - 332   2023.8

    　More details

    Language：Japanese   Publisher：(NPO)日本肺癌学会  

    researchmap

  • Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study. International journal

    Saori Takata, Kei Morikawa, Hisashi Tanaka, Hidetoshi Itani, Masashi Ishihara, Kazuya Horiuchi, Yasuhiro Kato, Shinnosuke Ikemura, Hideyuki Nakagawa, Yoshiro Nakahara, Yoshitaka Seki, Akihiro Bessho, Nobumasa Takahashi, Kentaro Hayashi, Takeo Endo, Kiyoshi Takeyama, Toshiya Maekura, Nagio Takigawa, Akikazu Kawase, Makoto Endoh, Kenji Nemoto, Kazuma Kishi, Kenzo Soejima, Yusuke Okuma, Kenichi Yoshimura, Daisuke Saigusa, Yae Kanai, Koji Ueda, Akira Togashi, Noriyuki Matsutani, Nobuhiko Seki

    Therapeutic advances in medical oncology   15   17588359231177021 - 17588359231177021   2023

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: The exosome-focused translational research for afatinib (EXTRA) study is the first trial to identify novel predictive biomarkers for longer treatment efficacy of afatinib in patients with epidermal growth factor receptor (EGFR) mutation-positive nonsmall cell lung cancer (NSCLC) via a comprehensive association study using genomic, proteomic, epigenomic, and metabolomic analyses. OBJECTIVES: We report details of the clinical portion prior to omics analyses. DESIGN: A prospective, single-arm, observational study was conducted using afatinib 40 mg/day as an initial dose in untreated patients with EGFR mutation-positive NSCLC. Dose reduction to 20 mg every other day was allowed. METHODS: Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated. RESULTS: A total of 103 patients (median age 70 years, range 42-88 years) were enrolled from 21 institutions in Japan between February 2017 and March 2018. After a median follow-up of 35.0 months, 21% remained on afatinib treatment, whereas 9% had discontinued treatment because of AEs. The median PFS was 18.4 months, with a 3-year PFS rate of 23.3%. The median afatinib treatment duration in patients with final doses of 40 (n = 27), 30 (n = 23), and 20 mg/day (n = 35), and 20 mg every other day (n = 18) were 13.4, 15.4, 18.8, and 18.3 months, respectively. The median OS was not reached, with a 3-year OS rate of 58.5%. The median OS in patients who did (n = 25) and did not (n = 78) receive osimertinib during the entire course of treatment were 42.4 months and not reached, respectively (p = 0.654). CONCLUSIONS: As the largest prospective study in Japan, this study confirmed favorable OS following first-line afatinib in patients with EGFR mutation-positive NSCLC in a real-world setting. Further analysis of the EXTRA study is expected to identify novel predictive biomarkers for afatinib. TRIAL REGISTRATION: UMIN-CTR identifier (UMIN000024935, https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_his_list.cgi?recptno=R000028688.

    DOI： 10.1177/17588359231177021

    PubMed

    researchmap

  • Clinical Characteristics and Risk Prediction Score in Patients With Mild-to-Moderate Coronavirus Disease 2019 in Japan. International journal

    Atsushi Marumo, Haruka Okabe, Hisae Sugihara, Junichi Aoyama, Yasuhiro Kato, Kensuke Arai, Yasuhiro Shibata, Etsu Fuse, Machiko Nomura, Kiyotaka Kohama

    Cureus   14 ( 11 )   e31210   2022.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, causing widespread mortality. Many patients with COVID-19 have been treated in homes, hotels, and medium-sized hospitals where doctors were responsible for assessing the need for critical care hospitalization. This study aimed to establish a severity prediction score for critical care triage. METHOD: We analyzed the data of 368 patients with mild-to-moderate COVID-19 who had been admitted to Fussa Hospital, Japan, from April 2020 to February 2022. We defined a high-oxygen group as requiring ≥4 l/min of oxygen. Multivariable logistic regression was used to construct a risk prediction score, and the best model was selected using a stepwise selection method. RESULTS: Multivariable analysis showed that older age (≥70 years), elevated creatine kinase (≥127 U/L), C-reactive protein (≥2.19 mg/dL), and ferritin (≥632.7 ng/mL) levels were independent risk factors associated with the high-oxygen group. Each risk factor was assigned a score ranging from 0 to 4, and we referred to the final overall score as the Fussa score. Patients were classified into two groups, namely, high-risk (total risk factors, ≥2) and low-risk (total risk score, <2) groups. The high-risk group had a significantly worse prognosis (low-risk group, undefined vs. high-risk group, undefined; P< 0.0001). CONCLUSIONS: The Fussa score might help to identify patients with COVID-19 who require critical care hospitalization.

    DOI： 10.7759/cureus.31210

    PubMed

    researchmap

  • Opioid-induced nausea and vomiting: a dexamethasone multicentre prospective study. Reviewed International journal

    Yusuke Takagi, Shuji Ota, Makiko Yomota, Masashi Ishihara, Yukio Hosomi, Kageaki Watanabe, Takeshi Honda, Yasuhiro Kato, Shoko Kawai, Takahiko Sakamoto, Terunobu Haruyama, Etsuko Aruga, Nobuhiko Seki

    BMJ supportive & palliative care   2022.4

    　More details

  • First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status. Reviewed International journal

    Shigemasa Takamizawa, Yusuke Okuma, Yasuhiro Kato, Taiki Hakozaki, Shingo Kitagawa, Yoshitaka Zenke

    Future oncology (London, England)   18 ( 3 )   291 - 300   2022.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Background: The efficacy of osimertinib as a first-line treatment for patients with poor performance status (PS) remains unclear. Patients & methods: This multicenter retrospective study evaluated patients treated with osimertinib between 2018 and 2020, with PS 2-4. Results: Among 36 patients with PS 2, the median progression-free survival (PFS), 1-year PFS, median overall survival (OS) and 1-year OS were 14.5 months, 65.4%, 18.1 months and 72.7%, respectively. Among 20 patients with PS 3-4, the median PFS, 1-year PFS, median OS and 1-year OS were 3.0 months, 27.1%, 5.0 months and 46.1%, respectively. Conclusion: Osimertinib was not as efficacious as other EGFR-tyrosine kinase inhibitors.

    DOI： 10.2217/fon-2021-0947

    PubMed

    researchmap

  • FoundationOneにて診断したHER2遺伝子変異陽性肺腺癌に対してTrastuzumab deruxtecanが奏効した1例

    鈴木 貴大, 宮永 晃彦, 加藤 祐樹, 加藤 泰裕, 中道 真仁, 松本 優, 峯岸 裕司, 野呂 林太郎, 久保田 馨, 清家 正博, 弦間 昭彦

    肺癌   61 ( 5 )   434 - 434   2021.10

    　More details

    Language：Japanese   Publisher：(NPO)日本肺癌学会  

    researchmap

  • Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations. Reviewed

    Yasuhiro Kato, Gou Yamamoto, Yasutaka Watanabe, Yuki Yamane, Hideaki Mizutani, Futoshi Kurimoto, Masahiro Seike, Akihiko Gemma, Kiwamu Akagi, Hiroshi Sakai

    International journal of clinical oncology   26 ( 6 )   1065 - 1072   2021.6

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    INTRODUCTION: MET exon 14 skipping mutation, observed in 3-4% of non-small cell lung cancer (NSCLC), is emerging as a targetable alteration. In recent years, immune checkpoint inhibitors (ICI) have been effective in treating several NSCLCs. Our research aimed to investigate the characteristics of patients with NSCLCs harboring MET exon 14 mutations and their response to ICI in Japan. METHODS: Among the 1954 consecutive NSCLCs diagnosed at Saitama Cancer Center between 2010 and 2019, MET exon 14 skipping mutations were detected in 68 (3.5%) NSCLCs. We evaluated their characteristics such as programmed cell death ligand 1 (PD-L1) expression. RESULTS: Median age of patients with NSCLCs harboring MET exon 14 skipping mutations was 73 years. PD-L1 was highly expressed in 17 (70.8%) of the 24 patients examined. Seven patients received ICI monotherapy, and three out of seven had a remarkable treatment response, resulted in objective response rate (ORR) of 42.9% and progression-free survival of 24.7 months. Three patients with donor splice-site mutations showed a long-term treatment response, despite the fact that two with acceptor splice-site mutations demonstrated no response and experienced early disease progression with ICI monotherapy. CONCLUSION: Our results indicated that patients with NSCLCs harboring MET exon 14 mutations presented with a high rate of positive PD-L1 expression. ICI treatment showed a high ORR and long-term efficacy for NSCLCs harboring MET exon 14 mutations. Variants of MET exon 14 splice-site mutations may be associated with ICI response.

    DOI： 10.1007/s10147-021-01893-0

    PubMed

    researchmap

  • Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report. Reviewed International journal

    Yuki Kato, Yasuhiro Kato, Yuji Minegishi, Takahiro Suzuki, Shinji Nakamichi, Masaru Matsumoto, Akihiko Miyanaga, Rintaro Noro, Kaoru Kubota, Yasuhiro Terasaki, Masahiro Seike, Akihiko Gemma

    OncoTargets and therapy   14   5315 - 5319   2021

    　More details

    Authorship：Corresponding author   Language：English  

    Antibody-drug conjugate (ADC) was novel type of anticancer drugs. Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2) targeting ADC, can be a novel treatment option for HER2 alternation (mutation, expression, amplification) advanced-stage non-small-cell lung cancer (NSCLC) from DESTINY-Lung01 result. Herein, we report a successful treatment with T-DXd for NSCLC harboring HER2 exon 20 insertion mutation in a patient with poor performance status (PS). We presented a case of a 52-year-old heavily pretreated female patient diagnosed with lung adenocarcinoma (cT1bN3M0, stage IIIB). After fifth-line pretreatment of systemic chemotherapy, primary tumor recurrence, pleural effusion, and miliary lung metastases were observed. The patient presented with hypoxia requiring oxygen therapy via nasal cannula at a flow rate of 4 L per minute, cancer pain, and cachexia requiring opioid treatment. Her Eastern Cooperative Oncology Group PS score was assessed 3. Comprehensive genomic profiling revealed HER2 exon 20 insertion mutation. After treatment with T-DXd was approved by the ethical review committee of Nippon Medical School Hospital, treatment was started. The tumor size decreased significantly, and her PS score decreased from 3 to 1, with improvement of hypoxia, cancer pain, and cachexia. The patient is still receiving treatment, without disease progression 6 months after starting treatment with T-DXd. Despite cases of poor PS, NGS should be performed and target therapy including ADCs should be considered.

    DOI： 10.2147/OTT.S341290

    PubMed

    researchmap

  • Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report. Reviewed International journal

    Yasuhiro Kato, Yasutaka Watanabe, Yuki Yamane, Hideaki Mizutani, Futoshi Kurimoto, Hiroshi Sakai

    Immunotherapy   12 ( 6 )   373 - 378   2020.4

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    Background: Tuberculosis (TB) is considered to be an adverse effect of treatment with immune checkpoint inhibitors. Methodology & results: Our case was a 75-year-old woman diagnosed with unresectable stage III non-small-cell lung cancer. After radical chemoradiotherapy was completed, durvalumab was initiated as a consolidation therapy. However, since chest CT showed appearances of infiltration shadows scattered in the periphery of the lungs after five doses of immunotherapy, duruvalumab was discontinued. 6 weeks later, the patient was aware of intermittent fever. Chest CT scan showed the appearance of a tree-in-bud pattern in the right lung. Acid-fast bacilli stain of sputum was positive and the PCR test was positive for Mycobacterium tuberculosis. Conclusion: Duruvalumab as PD-L1 blockade may activate TB.

    DOI： 10.2217/imt-2020-0061

    PubMed

    researchmap

  • P2.04-39 Clinical Characteristics of Long-Term Survivors with Nivolumab in Previously Treated Advanced NSCLC from Real World Data Reviewed

    Y. Watanabe, H. Mizutani, Y. Kato, Y. Yamane, F. Kurimoto, H. Sakai

    Journal of Thoracic Oncology   14 ( 10 )   S723 - S723   2019.10

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.jtho.2019.08.1544

    researchmap

  • EP1.01-20 A Single-Arm Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel Monotherapy After Standard Therapy for Advanced NSCLC

    Y. Kato, Y. Okuma, Y. Hosomi

    Journal of Thoracic Oncology   14 ( 10 )   S919 - S920   2019.10

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.jtho.2019.08.1995

    researchmap

  • A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer. Reviewed International journal

    Yasuhiro Kato, Yusuke Okuma, Kageaki Watanabe, Makiko Yomota, Shoko Kawai, Yukio Hosomi, Tatsuru Okamura

    Cancer chemotherapy and pharmacology   84 ( 2 )   351 - 358   2019.8

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Few studies have investigated the clinical efficacy of third- and later-line of chemotherapy after standard chemotherapy for previously treated advanced non-small cell lung cancer (NSCLC). We prospectively evaluated the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) following standard chemotherapies for previously treated advanced NSCLC. METHODS: The eligible patients having adequate organ functions with performance status 0-2 were enrolled after completing standard chemotherapy. They received weekly nab-paclitaxel 100 mg/m2 intravenously on days 1, 8, and 15 every 3 weeks. The primary end point was objective response rate (ORR). Median progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated as secondary end points. RESULTS: This trial was discontinued because of late accrual. Twenty two patients were enrolled from April 2013 and February 2019. The total ORR was 22.7% [95% CI 7.8-45.4] and disease control rate (DCR) was 81.8% [95% CI 59.7-94.8]. Median PFS was 3.4 months [95% CI 2.3-4.1] and median OS was 7.4 months [95% CI 4.2-10.7]. Median follow-up interval was 6.7 months hematological AEs of Grade 3/4 included anemia (18%), leukopenia (18%), and neutropenia (32%), while the most frequent nonhematological AEs were fatigue (50%) and peripheral neuropathy (36.4%). Severe AEs related to treatment were observed in only one patient. CONCLUSION: Nab-paclitaxel may be a safe and effective later-line chemotherapeutic option for previously treated advanced NSCLC after standard of chemotherapies based on other trials.

    DOI： 10.1007/s00280-019-03843-0

    PubMed

    researchmap

  • Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Reviewed International journal

    Yasuhiro Kato, Yukio Hosomi, Kageaki Watanabe, Makiko Yomota, Shoko Kawai, Yusuke Okuma, Kaoru Kubota, Masahiro Seike, Akihiko Gemma, Tatsuru Okamura

    Journal of thoracic disease   11 ( 6 )   2350 - 2360   2019.6

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Osimertinib exhibits good efficacy in patients with T790M-positive non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). Compared with the clinical trials, in real-world clinical practice, osimertinib must be administered to older patients and those with poor Eastern Cooperative Oncology Group performance status (ECOG-PS). Therefore, we investigated the association between osimertinib efficacy/safety and PS score, age, and other clinical features in patients with T790M-positive NSCLC. METHODS: We reviewed all patients with T790M-positive NSCLC and acquired resistance to initial EGFR-TKIs who were administered osimertinib between March 2016 and January 2018 at the Tokyo Metropolitan Cancer and Infectious Diseases Center in Komagome Hospital, Japan. RESULTS: In total, 31 patients, including 8 young (<65 years) and 23 elderly (≥65 years) patients, were included in the study. Of these, 10 (32.3%) patients had poor PS scores. The progression-free survival (PFS) was significantly shorter in young patients was than elderly patients [3.5 vs. 6.4 months, P=0.041; hazard ratio (HR), 2.41]. The overall survival (OS) of the young patients tended to be shorter than that of the elderly patients (5.3 vs. 19.4 months, P=0.067; HR, 2.58). The PFS (9.1 vs. 5.5 months; P=0.071; HR, 0.38) and the OS (not reached vs. 6.6 months, P=0.061; HR, 0.39) were shorter in patients with poor ECOG-PS than those with good ECOG-PS. The toxic effects of osimertinib were manageable. By multivariate analysis, both age and ECOG-PS were independent predictors of osimertinib efficacy. CONCLUSIONS: Poor ECOG-PS and younger age were associated with lower efficacy of osimertinib in T790M-positive NSCLC.

    DOI： 10.21037/jtd.2019.06.03

    PubMed

    researchmap

  • Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report. Reviewed International journal

    Maiko Asai, Yasuhiro Kato, Shoko Kawai, Kageaki Watanabe, Makiko Yomota, Yusuke Okuma, Yukio Hosomi, Tsunekazu Hishima, Tatsuru Okamura

    Immunotherapy   11 ( 6 )   467 - 472   2019.4

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    Immuno-checkpoint inhibitor response and immune-related adverse events remain controversial issues. Managing pericardial effusion during programmed cell death 1 inhibitor treatment is challenging. Here, we report a case of successfully managed cardiac tamponade caused by nivolumab-induced pseudoprogression. A 62-year-old male diagnosed with advanced lung adenocarcinoma started on nivolumab. Seven days later, he experienced cardiac tamponade and required pericardiocentesis, and other lesions were larger on computed tomography. The patient's condition stabilized after pericardiocentesis. However, although the lesions other than pericardial effusion were reduced on chest CT, cardiac tamponade recurred after 6 weeks. We considered that the case involved cardiac tamponade induced by pseudoprogression and administered intrapericardial bleomycin after pericardiocentesis. Thereafter, the patient was administered nivolumab for 7 months until disease progression.

    DOI： 10.2217/imt-2019-0003

    PubMed

    researchmap

  • ProGRP as early predictive marker of non-small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment. Reviewed International journal

    Yasuhiro Kato, Yosuke Tanaka, Mitsunori Hino, Akihiko Gemma

    Respiratory medicine case reports   27   100837 - 100837   2019

    　More details

    Authorship：Lead author   Language：English  

    We report a case of non-small-cell lung cancer (NSCLC) to small-cell lung cancer (SCLC) transformation after epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. The patient was a man who diagnosed with EGFR-mutant advanced NSCLC. After he was introduced afatinib, his tumor had been reduced by the treatment. However, plasma pro-gastrin-releasing peptide (ProGRP) became higher with disease progression, and SCLC was detected at the second biopsy. It is suggested that elevation of plasma ProGRP level before EGFR-TKI therapy is useful for predicting EGFR-mutant NSCLC to SCLC transformation.

    DOI： 10.1016/j.rmcr.2019.100837

    PubMed

    researchmap

  • P3.01-53 Comparison of the Treatment Efficacy of Osimertinib in Young and Elderly Patients with T790M-Positive NSCLC

    Y. Kato, Y. Hosomi

    Journal of Thoracic Oncology   13 ( 10 )   S887 - S887   2018.10

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.jtho.2018.08.1613

    researchmap

  • Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer. Reviewed International journal

    Yasuhiro Kato, Jumpei Kashima, Kageaki Watanabe, Makiko Yomota, Yositaka Zenke, Yusuke Okuma, Yukio Hosomi, Akihiko Gemma, Masahiro Seike, Tatsuru Okamura

    Anticancer research   38 ( 2 )   1077 - 1083   2018.2

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND/AIM: Programmed cell death ligand 1 (PD-L1) expression is a predictive marker for immunotherapy effects in advanced non-small cell lung cancer (NSCLC), but its association with patient characteristics or specimens is controversial. We aimed to retrospectively analyze the association of PD-L1 expression with clinicopathological features of NSCLC patients. MATERIALS AND METHODS: The PD-L1 expression and clinicopathological features of NSCLC patients were assessed from January 2017 to June 2017 in the Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital were reviewed (n=108). RESULTS: For PD-L1 expressions of 0% and >1%, multivariate analysis showed that lymph node sample results were associated with positive PD-L1 expression. Archival samples and high serum carcinoembryonic antigen (CEA) levels were associated with negative PD-L1 expression. Sample preservation time and CEA levels correlated with PD-L1 expression. CONCLUSION: Nodal metastasis, sample preservation time and CEA levels were associated with PD-L1 expression in NSCLC.

    PubMed

    researchmap

  • P2.07-031 Relationship between Clinical Factors and the Expression of Programmed Death Ligand 1 in Lung Cancer

    Y. Kato, K. Watanabe, J. Kashima, K. Hashimoto, A. Fukuda, A. Mitsuhashi

    Journal of Thoracic Oncology   12 ( 11 )   S2427 - S2427   2017.11

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.jtho.2017.11.090

    researchmap

  • INVESTIGATION OF UTILITY OF EBUS-TBNA IN THE DIAGNOSIS OF SARCOIDOSIS

    Yasuhiro Kato, Yasuhiro Kato, Yosuke Tanaka, Mitsunori Hino

    RESPIROLOGY   20   24 - 24   2015.12

    　More details

    Language：English   Publisher：WILEY-BLACKWELL  

    Web of Science

    researchmap

  • 2ND INTERIM REPORT: EFFECT OF TIOTROPIUM MONOTHERAPY VERSUS TIOTROPIUM PLUS INDACATEROL IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE-SINGLE-CENTRE, RANDOMIZED, PROSPECTIVE, REAL-WORLD STUDY

    Yosuke Tanaka, Mitsunori Hino, Akihiko Gemma, Yumiko Kobayashi, Yasuhiro Katoh

    RESPIROLOGY   20   37 - 37   2015.12

    　More details

    Language：English   Publisher：WILEY-BLACKWELL  

    Web of Science

    researchmap

  • INFLUENCE OF INFLUENZA VIRUS INFECTION ON HOSPITALIZATION DUE TO PNEUMONIA OF VERY ELDERLY JAPANESE PATIENTS

    Mitsunori Hino, Yosuke Tanaka, Naomi Onda, Yasuhiro Katoh, Yumiko Kobayashi, Seiji Kosaihira, Norihisa Motohashi, Teruyoshi Ookubo

    RESPIROLOGY   20   138 - 138   2015.12

    　More details

    Language：English   Publisher：WILEY-BLACKWELL  

    Web of Science

    researchmap

  • Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report. Reviewed International journal

    Aya Fukuizumi, Akihiko Miyanaga, Masahiro Seike, Yasuhiro Kato, Shinji Nakamichi, Kumi Chubachi, Masaru Matsumoto, Rintaro Noro, Yuji Minegishi, Shinobu Kunugi, Kaoru Kubota, Akihiko Gemma

    BMC research notes   8   165 - 165   2015.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Non-small-cell lung cancers (NSCLCs) harboring translocations in anaplastic lymphoma kinase (ALK) are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib. CASE PRESENTATION: We describe a case of post-operative local recurrence of lung adenocarcinoma in an 81 year-old male. He underwent radiation and received chemotherapy with docetaxel, but neither treatment regimen was effective. Following identification of ALK rearrangements, crizotinib treatment was initiated. After treatment with crizotinib for 5 days, adverse events including acute renal failure (grade 2/CTCAE ver4.0) and congestive heart failure (grade 3) occurred. Crizotinib modified treatment was required. Half dose of crizotinib treatment could not control tumor progression. Ultimately, crizotinib was administrated at a dose of 250 mg twice daily every 3 day dosing for 13 months with maintenance of the anti-tumor effect. CONCLUSION: This is the first case report that skip schedule was more effective than dose reduction daily in crizotinib administration for ALK rearranged NSCLC patient with severe adverse events.

    DOI： 10.1186/s13104-015-1126-8

    PubMed

    researchmap

▼display all

Books

  • がん薬物療法看護ベスト・プラクティス

    下山, 達, 三浦, 里織, 佐々木, 常雄（肺癌）

    照林社  2020.3  （ ISBN:9784796524797 ）

    　More details

    Total pages：x, 413p   Language：Japanese  

    CiNii Books

    researchmap

  • オンコロジークリニカルガイド 肺癌化学療法

    弦間, 昭彦, 里内, 美弥子（第3世代EGFR-TKIによる治療にかかわる比較試験）

    南山堂  2019.8  （ ISBN:4525424524 ）

    　More details

    Total pages：375   Language：Japanese  

    CiNii Books

    ASIN

    researchmap

Misc.

▼display all

Awards

  • Best Oral Presentation

    2023.10   The 3rd Internastional Congress of the Asian Oncolog Society  

    　More details

  • 一般社団法人日本癌治療学会第22回研究奨励賞

    2022   Japan Society of Clinical Oncology   Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations.

    Yasuhiro Kato

    　More details